Skip Navigation LinksHome > May 2014 - Volume 114 - Issue 5 > New Drug for Type 2 Diabetes
AJN, American Journal of Nursing:
doi: 10.1097/01.NAJ.0000446775.69028.fc
Drug Watch

New Drug for Type 2 Diabetes

Aschenbrenner, Diane S. MS, RN

Collapse Box

Abstract

* A new sodium–glucose cotransporter 2 inhibitor, dapagliflozin (Farxiga), has been approved to control type 2 diabetes.

* Hypotension is possible with dapagliflozin use, and the drug can alter renal function. Hypovolemia should be corrected prior to the start of treatment. Kidney function and glucose levels should be assessed throughout therapy.

* The most common adverse effects are genital yeast infections, nasopharyngitis, and urinary tract infections.

© 2014 Lippincott Williams & Wilkins. All rights reserved.

Login